A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome

Nathan Silver, Richard Allen, Julia Senerth, Christopher J Earley

Research output: Contribution to journalArticle

Abstract

Background: Restless legs syndrome (RLS) is a chronic disease, which is managed with palliative medications that are likely to be required for a patient's lifetime. It is, therefore, important to know the long-term consequences of these treatments. Currently, the most commonly prescribed treatment for RLS is one of the dopamine (DA) agonists. Most of what we understand about efficacy and side effects of the DA agonists are, however, derived from relatively short-term studies. This is particularly a problem since these medications produce in some patients a significant increase or augmentation of RLS symptoms known to occur during the first 2. years of treatment and perhaps even later in treatment. The primary aim of this study was to determine the long-term efficacy (10-year) for commonly used RLS medication types: dopaminergic agonists and opioids. Methods: Records of all RLS patients treated in one tertiary care center with pramipexole, pergolide or methadone during the years 1997-2007 were reviewed. The duration and reason for any discontinuation of treatment and medication doses were recorded. Results: Annual rates for discontinuing treatment persisted for up to 10. years of treatment and were fairly constant after the first year at 9% for pramipexole, 8% for pergolide, and 0% for methadone. Similarly, annual augmentation rates were fairly constant after the first year and persisted for up to 10. years at 7% for pramipexole, 5% for pergolide, and 0% for methadone. The percentage continuing on the treatment medication for over 5. years was 58% for pramipexole and 35% for pergolide. Conclusions: The DA agonists appear to have a limited period of clinical utility for many patients. Severe augmentation, while not common in any 1. year, can develop even after years on the medication. Methadone, in contrast, shows neither augmentation nor major problems with continued efficacy after the first year of treatment.

Original languageEnglish (US)
Pages (from-to)440-444
Number of pages5
JournalSleep Medicine
Volume12
Issue number5
DOIs
StatePublished - May 2011

Fingerprint

Restless Legs Syndrome
Methadone
Dopamine Agonists
Pergolide
Therapeutics
Tertiary Care Centers
Opioid Analgesics
Chronic Disease

Keywords

  • Dopamine agonist
  • Long-term follow-up
  • Methadone
  • Opioid
  • Pergolide
  • Pramipexole
  • Restless legs augmentation
  • Restless legs syndrome

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. / Silver, Nathan; Allen, Richard; Senerth, Julia; Earley, Christopher J.

In: Sleep Medicine, Vol. 12, No. 5, 05.2011, p. 440-444.

Research output: Contribution to journalArticle

@article{5e1cdc527b5b4478b8aec1b5a3e989c1,
title = "A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome",
abstract = "Background: Restless legs syndrome (RLS) is a chronic disease, which is managed with palliative medications that are likely to be required for a patient's lifetime. It is, therefore, important to know the long-term consequences of these treatments. Currently, the most commonly prescribed treatment for RLS is one of the dopamine (DA) agonists. Most of what we understand about efficacy and side effects of the DA agonists are, however, derived from relatively short-term studies. This is particularly a problem since these medications produce in some patients a significant increase or augmentation of RLS symptoms known to occur during the first 2. years of treatment and perhaps even later in treatment. The primary aim of this study was to determine the long-term efficacy (10-year) for commonly used RLS medication types: dopaminergic agonists and opioids. Methods: Records of all RLS patients treated in one tertiary care center with pramipexole, pergolide or methadone during the years 1997-2007 were reviewed. The duration and reason for any discontinuation of treatment and medication doses were recorded. Results: Annual rates for discontinuing treatment persisted for up to 10. years of treatment and were fairly constant after the first year at 9{\%} for pramipexole, 8{\%} for pergolide, and 0{\%} for methadone. Similarly, annual augmentation rates were fairly constant after the first year and persisted for up to 10. years at 7{\%} for pramipexole, 5{\%} for pergolide, and 0{\%} for methadone. The percentage continuing on the treatment medication for over 5. years was 58{\%} for pramipexole and 35{\%} for pergolide. Conclusions: The DA agonists appear to have a limited period of clinical utility for many patients. Severe augmentation, while not common in any 1. year, can develop even after years on the medication. Methadone, in contrast, shows neither augmentation nor major problems with continued efficacy after the first year of treatment.",
keywords = "Dopamine agonist, Long-term follow-up, Methadone, Opioid, Pergolide, Pramipexole, Restless legs augmentation, Restless legs syndrome",
author = "Nathan Silver and Richard Allen and Julia Senerth and Earley, {Christopher J}",
year = "2011",
month = "5",
doi = "10.1016/j.sleep.2010.11.002",
language = "English (US)",
volume = "12",
pages = "440--444",
journal = "Sleep Medicine",
issn = "1389-9457",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome

AU - Silver, Nathan

AU - Allen, Richard

AU - Senerth, Julia

AU - Earley, Christopher J

PY - 2011/5

Y1 - 2011/5

N2 - Background: Restless legs syndrome (RLS) is a chronic disease, which is managed with palliative medications that are likely to be required for a patient's lifetime. It is, therefore, important to know the long-term consequences of these treatments. Currently, the most commonly prescribed treatment for RLS is one of the dopamine (DA) agonists. Most of what we understand about efficacy and side effects of the DA agonists are, however, derived from relatively short-term studies. This is particularly a problem since these medications produce in some patients a significant increase or augmentation of RLS symptoms known to occur during the first 2. years of treatment and perhaps even later in treatment. The primary aim of this study was to determine the long-term efficacy (10-year) for commonly used RLS medication types: dopaminergic agonists and opioids. Methods: Records of all RLS patients treated in one tertiary care center with pramipexole, pergolide or methadone during the years 1997-2007 were reviewed. The duration and reason for any discontinuation of treatment and medication doses were recorded. Results: Annual rates for discontinuing treatment persisted for up to 10. years of treatment and were fairly constant after the first year at 9% for pramipexole, 8% for pergolide, and 0% for methadone. Similarly, annual augmentation rates were fairly constant after the first year and persisted for up to 10. years at 7% for pramipexole, 5% for pergolide, and 0% for methadone. The percentage continuing on the treatment medication for over 5. years was 58% for pramipexole and 35% for pergolide. Conclusions: The DA agonists appear to have a limited period of clinical utility for many patients. Severe augmentation, while not common in any 1. year, can develop even after years on the medication. Methadone, in contrast, shows neither augmentation nor major problems with continued efficacy after the first year of treatment.

AB - Background: Restless legs syndrome (RLS) is a chronic disease, which is managed with palliative medications that are likely to be required for a patient's lifetime. It is, therefore, important to know the long-term consequences of these treatments. Currently, the most commonly prescribed treatment for RLS is one of the dopamine (DA) agonists. Most of what we understand about efficacy and side effects of the DA agonists are, however, derived from relatively short-term studies. This is particularly a problem since these medications produce in some patients a significant increase or augmentation of RLS symptoms known to occur during the first 2. years of treatment and perhaps even later in treatment. The primary aim of this study was to determine the long-term efficacy (10-year) for commonly used RLS medication types: dopaminergic agonists and opioids. Methods: Records of all RLS patients treated in one tertiary care center with pramipexole, pergolide or methadone during the years 1997-2007 were reviewed. The duration and reason for any discontinuation of treatment and medication doses were recorded. Results: Annual rates for discontinuing treatment persisted for up to 10. years of treatment and were fairly constant after the first year at 9% for pramipexole, 8% for pergolide, and 0% for methadone. Similarly, annual augmentation rates were fairly constant after the first year and persisted for up to 10. years at 7% for pramipexole, 5% for pergolide, and 0% for methadone. The percentage continuing on the treatment medication for over 5. years was 58% for pramipexole and 35% for pergolide. Conclusions: The DA agonists appear to have a limited period of clinical utility for many patients. Severe augmentation, while not common in any 1. year, can develop even after years on the medication. Methadone, in contrast, shows neither augmentation nor major problems with continued efficacy after the first year of treatment.

KW - Dopamine agonist

KW - Long-term follow-up

KW - Methadone

KW - Opioid

KW - Pergolide

KW - Pramipexole

KW - Restless legs augmentation

KW - Restless legs syndrome

UR - http://www.scopus.com/inward/record.url?scp=79955114643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955114643&partnerID=8YFLogxK

U2 - 10.1016/j.sleep.2010.11.002

DO - 10.1016/j.sleep.2010.11.002

M3 - Article

C2 - 21239226

AN - SCOPUS:79955114643

VL - 12

SP - 440

EP - 444

JO - Sleep Medicine

JF - Sleep Medicine

SN - 1389-9457

IS - 5

ER -